Search Results | Blood | American Society of Hematology

1-20 of 215

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Blood (2021) 138 (19): 1901–1905.

DOI: https://doi.org/10.1182/blood.2021012319

Published: 2021

Includes: Supplemental data

Journal Articles

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM)

Blood (2021) 138 (Supplement 1): 1596.

DOI: https://doi.org/10.1182/blood-2021-145968

Published: 2021

Journal Articles

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Blood (2021) 138 (Supplement 1): 2719.

DOI: https://doi.org/10.1182/blood-2021-149192

Published: 2021

Journal Articles

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood (2021) 138 (Supplement 1): 2720.

DOI: https://doi.org/10.1182/blood-2021-149222

Published: 2021

Journal Articles

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood (2021) 138 (Supplement 1): 2721.

DOI: https://doi.org/10.1182/blood-2021-149594

Published: 2021

Journal Articles

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Blood (2021) 138 (Supplement 1): 544.

DOI: https://doi.org/10.1182/blood-2021-151557

Published: 2021

Journal Articles

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Blood (2021) 138 (Supplement 1): 466.

DOI: https://doi.org/10.1182/blood-2021-146798

Published: 2021

Journal Articles

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 541.

DOI: https://doi.org/10.1182/blood-2021-150092

Published: 2021

Journal Articles

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

David F. Moreno, Sara Paz, Mari-Pau Mena, Monica Lopez-Guerra, Aina Oliver-Caldes, Anthony M Battram, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, M. Teresa Cibeira, Raquel Jiménez-Segura, Joan Bladé Creixenti, Laura Rosinol, Dolors Colomer, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 462.

DOI: https://doi.org/10.1182/blood-2021-147168

Published: 2021

Journal Articles

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Blood (2021) 138 (Supplement 1): 76.

DOI: https://doi.org/10.1182/blood-2021-146535

Published: 2021

Journal Articles

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

Paula Rodríguez-Otero, Veronica Gonzalez De La Calle, Anna Sureda, Felipe De Arriba, Marta Reinoso Segura, Paz Ribas, Ana Pilar Gonzalez, Yolanda Gonzalez-Montes, Albert Oriol, Joaquín Martínez-López, Marta Sonia Gonzalez, Miguel T Hernández, Maialen Sirvent, Joan Bladé Creixenti, Juan Jose Lahuerta, Jesús F. San-Miguel, Maria-Victoria Mateos

Blood (2021) 138 (Supplement 1): 1677.

DOI: https://doi.org/10.1182/blood-2021-147725

Published: 2021

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

DOI: https://doi.org/10.1182/blood-2021-148423

Published: 2021

Journal Articles

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Blood (2021) 137 (1): 49–60.

DOI: https://doi.org/10.1182/blood.2020006731

Published: 2021

Includes: Supplemental data

Journal Articles

A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform

Blood (2020) 136 (Supplement 1): 34–37.

DOI: https://doi.org/10.1182/blood-2020-137021

Published: 2020

Journal Articles

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations

Blood (2020) 136 (Supplement 1): 20–22.

DOI: https://doi.org/10.1182/blood-2020-136000

Published: 2020

Journal Articles

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Blood (2020) 136 (Supplement 1): 8–9.

DOI: https://doi.org/10.1182/blood-2020-140934

Published: 2020

Journal Articles

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Blood (2020) 136 (Supplement 1): 5–6.

DOI: https://doi.org/10.1182/blood-2020-136258

Published: 2020

Journal Articles

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis

Blood (2020) 136 (Supplement 1): 22–23.

DOI: https://doi.org/10.1182/blood-2020-136466

Published: 2020

Journal Articles

HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients

Blood (2020) 136 (Supplement 1): 44–46.

DOI: https://doi.org/10.1182/blood-2020-136856

Published: 2020

Journal Articles

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Ignacio Isola, MD, David Moreno, MD, Esther Moga, MD PhD, Mari-Pau Mena, PhD, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, MD PhD, M. Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Carlos Fernandez de Larrea, MD PhD

Blood (2020) 136 (Supplement 1): 2–3.

DOI: https://doi.org/10.1182/blood-2020-139737

Published: 2020

2 3 4 5

NARROW

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM)

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis

HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only